Literature DB >> 19501511

On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.

Marina Gálvez-Peralta1, Jennifer S Hackbarth, Karen S Flatten, Scott H Kaufmann, Hiroshi Hiasa, Chenguo Xing, David M Ferguson.   

Abstract

The cytotoxicity and mechanism of action of a series of substituted 9-aminoacridines is evaluated using topoisomerase I and cancer cell growth inhibition assays. In previous work, compounds of this type were shown to catalytically inhibit topoisomerase II, leading to a G1-S phase arrest of the cell cycle and apoptosis in pancreatic cancer cells in vitro and in vivo. The present study expands the potential utility of these compounds in the development of cancer therapeutics by showing that these compounds inhibit proliferation of cell lines derived from the nine most common human cancers. Further results show that at least one of the compounds effectively stabilizes topoisomerase I-DNA adduct formation in intact cells. RNA interference experiments, however, indicate that this interaction does not contribute to the drug-induced killing of cancer cells indicating the compounds may be non-lethal poisons of topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501511      PMCID: PMC2845530          DOI: 10.1016/j.bmcl.2009.05.037

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.

Authors:  J A Holden
Journal:  Curr Med Chem Anticancer Agents       Date:  2001-05

Review 2.  DNA topoisomerase II as a target for cancer chemotherapy.

Authors:  Jerrylaine V Walker; John L Nitiss
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

3.  Action of camptothecin on mammalian cells in culture.

Authors:  L H Li; T J Fraser; E J Olin; B K Bhuyan
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

4.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

Authors:  J Nitiss; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Authors:  W K Eng; L Faucette; R K Johnson; R Sternglanz
Journal:  Mol Pharmacol       Date:  1988-12       Impact factor: 4.436

6.  Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

Authors:  K Wassermann; J Markovits; C Jaxel; G Capranico; K W Kohn; Y Pommier
Journal:  Mol Pharmacol       Date:  1990-07       Impact factor: 4.436

7.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

Authors:  Y H Hsiang; M G Lihou; L F Liu
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

8.  Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

Authors:  Lisa M Oppegard; Andrei V Ougolkov; Doris N Luchini; Renee A Schoon; John R Goodell; Harneet Kaur; Daniel D Billadeau; David M Ferguson; Hiroshi Hiasa
Journal:  Eur J Pharmacol       Date:  2008-12-03       Impact factor: 4.432

9.  Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D.

Authors:  D K Trask; M T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

View more
  1 in total

1.  9-AAA inhibits growth and induces apoptosis in human melanoma A375 and rat prostate adenocarcinoma AT-2 and Mat-LyLu cell lines but does not affect the growth and viability of normal fibroblasts.

Authors:  Włodzimierz Korohoda; Anna Hapek; Monika Pietrzak; Damian Ryszawy; Zbigniew Madeja
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.